Main Topic Area
All Topic Areas
1 - 10 of 253 more >>
Articles
1 - 5 of 50 more >>
- Bone Marrow and Peripheral Blood Stem Cell Transplantation: Q & A
Key Points Hematopoietic or blood-forming stem cells are immature cells that can mature into blood cells. These stem cells are found in the bone marrow, bloodstream, or umbilical cord blood (see Question 1). Bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) are procedures that restore stem cells that were destroyed by high doses of chemotherapy and/or radiation therapy (see Questions 2 and 3). In general, patients are less likely to develop a complication...
- NIGMS Center Grants to Explore Stem Cell Biology
Bethesda, Maryland Flexible in their fate, human embryonic stem cells can become any one of the more than 200 cell types that make up the human body. Because of this flexibility, stem cells hold promise for solving mysteries about the fundamental biology of all cells. "America's scientists need powerful tools to find better ways to diagnose and treat health problems," said Health and Human Services Secretary Tommy G. Thompson. "Understanding the biology of stem cells can help fill in the...
National Institutes of Health
- Sickle Cell Anemia
Sickle cell anemia affects the red blood cells. Normal red blood cells are smooth and round like doughnuts. They move easily through blood vessels to carry oxygen to all parts of the body. In sickle cell anemia, the red blood cells become hard, sticky, and shaped like sickles or crescents. When these hard and pointed red cells go through the small blood vessels, they tend to get stuck and block the flow of blood. This can cause pain, damage, and a low blood count or anemia. The sickle-shaped...
National Heart, Lung, and Blood Institute Information Center, NHLBI, NIH, HHS
- High Blood Pressure in the Lungs a Major Risk for Death in Adults with Sickle Cell Disease
A new study reveals that nearly one third of adults with sickle cell disease develop high blood pressure in their lungs and that the condition, known as pulmonary hypertension, causes a much higher death rate in patients with the complication than those without it. The findings, according to researchers from the Warren Grant Magnuson Clinical Center at the National Institutes of Health (NIH), demonstrate an urgent need to diagnose this complication in adults with sickle cell disease as it is a...
National Institutes of Health
- Hydroxyurea Therapy Improves Survival in Most Severely Affected Sickle Cell Patients
Sickle cell anemia patients who took the drug hydroxyurea over a 9-year period experienced a 40 percent reduction in deaths, according to the first study to evaluate whether the treatment prolongs life, announced the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health. The study of 299 adult sickle cell patients with moderate to severe forms of the disease, found that improved survival was related to the benefits associated with hydroxyurea treatment an...
National Institutes of Health
Organizations
1 - 5 of 7 more >>
- The Leukemia and Lymphoma Society - http://www.leukemia-lymphoma.org/hm_lls
- Leukemia & Lymphoma Society -
- Sickle Cell Information Center, The - http://www.scinfo.org/
- Sickle Cell Disease Association of America -
- Sickle Cell Disease Association of America, Inc. - http://www.sicklecelldisease.org
News
1 - 5 of 3227 more >>
- Study Examines Second Cancer Risk Among Hairy Cell Leukemia Survivors
MedicalNewsToday - Sat, 10 Feb 2007 01:00 EST
- Study Examines Second Cancer Risk Among Hairy Cell Leukemia Survivors
ScienceDaily - Thu, 08 Feb 2007 04:00 EST
- Really?: The Claim: Mother’s Heartburn Means a Hairy Newborn
New York Times - Mon, 19 Feb 2007 11:29 EST
- Leukemia Drug Turns Mini-molecules Up, Cancer Genes Down
MedicalNewsToday - Tue, 06 Mar 2007 03:00 EST
- Leukemia Drug Turns Mini-molecules Up, Cancer Genes Down
ScienceDaily - Mon, 05 Mar 2007 04:00 EST
Clinical Trials
1 - 5 of 5404 more >>
- Analysis of Blood and Bone Marrow to Detect Residual Disease in Patients With Previously Treated Hairy Cell Leukemia
ClinicalTrials.gov Identifier: NCT00005619 - Active, not recruiting
refractory hairy cell leukemia; progressive hairy cell leukemia, initial treatment
- Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia
ClinicalTrials.gov Identifier: NCT00003746 - Active, not recruiting
untreated hairy cell leukemia; progressive hairy cell leukemia, initial treatment; Prolymphocytic Leukemia
- Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine Therapy
ClinicalTrials.gov Identifier: NCT00003757 - Active, not recruiting
refractory hairy cell leukemia; progressive hairy cell leukemia, initial treatment
- BL22 Immunotoxin to Treat Hairy Cell Leukemia
ClinicalTrials.gov Identifier: NCT00071318 - Recruiting
Leukemia, Hairy Cell
- VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
ClinicalTrials.gov Identifier: NCT00049686 - Active, not recruiting
acute leukemia; atypical chronic myeloid leukemia; chronic leukemia; Hairy Cell Leukemia; myelodysplastic and myeloproliferative disease; ...

Not Signed In -

